MRI lab measurements in adults with type 3 Gaucher disease
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at MRI-based lab measurements (similar to a special type of scan) to find markers that reflect health in people with type 3 Gaucher disease. It may help researchers track the disease over time and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be able to understand the study and sign written consent.
- Your Gaucher disease should be medically stable, based on the study doctor.
- You must be able to have blood drawn for the study.
- You must be able to safely complete an MRI scan (about 30+ minutes), including staying still and handling enclosed spaces.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy, VGN-R08b, for people with type 3 Gaucher disease. It aims to see if the treatment is safe and can help with neurological symptoms like eye movement problems.
This trial tests a new daily pill called nizubaglustat (AZ-3102) for Gaucher disease type 3 (GD3). The pill aims to treat the disease by reducing the buildup of fatty substances in cells, which may help improve symptoms like anemia, low platelets, and enlarged spleen.
This study looks at how enzyme replacement therapy affects heart function in children with Gaucher disease type 3. It aims to see if the therapy helps keep the heart healthy.
This trial tests a treatment called velaglucerase beta, which replaces an enzyme that people with Gaucher disease lack. It may help reduce enlarged spleen and liver, improve anemia, and increase platelet counts in children under 12.
This study measures inflammation and “oxidative stress” (cell stress caused by imbalance in the body) using blood biomarkers in adults with Gaucher disease. It may help researchers understand what’s happening in the body and how treatment status relates to these blood signals.
This study looks for tiny particles in blood (called extracellular vesicles) that may help identify Gaucher disease and could guide future treatments. It also studies people who have Gaucher gene carrier status but do not have the disease, using careful genetic testing.
Hear when a new Gaucher Disease Type 3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.